Table 2.
Provides a summary of the primary references dealing with its analgesic and anti-inflammatory effects.
| Model | Dose/Method/Period | Activity | Refs. |
|---|---|---|---|
| Glial cell type BV2 | 1, 10, 100, 1000 μg mL−1; culture; 24 h | COX-2 mRNA, iNOS mRNA the synthesis of prostaglandin E2 the production of nitric oxide |
[121] |
| Cell line RAW 264.7 | 1, 10, 100 mmol L−1; culture; 6 h | At a concentration of 1 mM, TNF-α and IL-1β mRNA Amygdalin does not inhibit TNF-α and IL-1β mRNA expression in a dose-dependent manner. |
[123] |
| SD male rats with Carrageenan-induced arthritis pain model | 0.005, 0.05 and 0.1 mg kg−1; im; 8 h | At a concentration of 0.005 mg/kg, Fos, TNF-α and IL-1β; However, no analgesic effect of amygdalin was observed at doses greater than 0.005 mg/kg |
[123] |
| Modeling pain via plantar injection of formalin in SD male rats | 0.1, 0.5, 1.0 and 10.0 mg kg−1; Plantar injection | C-Fos, TNF-α, IL-1β Laetrile reduces pain in a dose-dependent manner in a dose range of less than 1 mg/kg. |
[123] |
| Type II collagen-induced CIA model, Wistar rats | 120 mg kg−1; gavage; 28 days | TNF-α and sICAM-1 | [125] |
| The BALB/c Mice | 0.5, 1 and 2 mg kg−1; ip; 7 h | NF-κB Reduced pulmonary edema in a dose-dependent manner. |
[126] |
| RAW264.7 cells | 6.25, 12.5, 25, 50, 100, 200, 400 µmol L−1; culture; 24 h | IL-17A, IL-23, CCL2 and CCL5 mRNA p-p38 the viability of RAW264.7 cell |
[127] |